FDA Holds Hearing on CBD as CA Moves Forward on Hemp
About 100 people testified at a public hearing held on May 31 by the FDA “in order to inform the regulatory path forward” on CBD. Manufacturers, researchers, doctors, laboratory representatives, lawyers and advocates (pro and con) were among those who spoke. Speakers expressed concern over the lack of uniformity and purity of available CBD preparations, and a lack of safety studies on vulnerable populations like children, seniors, pregnant women, and those taking other drugs.
NORML submitted comments to the FDA asking the agency to “craft benchmark safety and quality standards for hemp-derived CBD products in order to increase consumer satisfaction and confidence as this nascent industry transitions and matures into a legal marketplace.”…
A new report from Applied Development Economics (ADE) in Walnut Creek, CA estimates that the passage of

